Atacicept, a homodimeric fusion protein for the potential treatment of diseases triggered by plasma cells.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Current opinion in investigational drugs

• Publication date

  2008-11-01

• Fields of study

  Medicine

• Identifiers
  PMID 18951301
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I Clinical Study of Atacicept in Patients with Relapsed and Refractory B-Cell Non–Hodgkin's Lymphoma

  2008cited by this paper
• TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts.

  2008cited by this paper
• Pharmacokinetics and Biological Activity of Atacicept in Patients With Rheumatoid Arthritis

  2008cited by this paper
• Atacicept (TACI-Ig) inhibits growth of TACIhigh primary myeloma cells in SCID-hu mice and in coculture with osteoclasts

  2008cited by this paper
• Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study.

  2008cited by this paper
• Cutting Edge: The Dependence of Plasma Cells and Independence of Memory B Cells on BAFF and APRIL1

  2008cited by this paper
• TACI, an enigmatic BAFF/APRIL receptor, with new unappreciated biochemical and biological properties.

  2008cited by this paper
• Biologic therapies in rheumatology: lessons learned, future directions

  2007cited by this paper
• Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers

  2007cited by this paper
• Corticosterone inhibits the lipid-mobilizing effects of oleoyl-estrone in adrenalectomized rats.

  2007cited by this paper
• B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia.

  2006cited by this paper
• An APRIL to remember: novel TNF ligands as therapeutic targets

  2006cited by this paper
• B cells move to centre stage: novel opportunities for autoimmune disease treatment

  2006cited by this paper
• Influenza Virus Host Response of C57Bl/6 Mice Treated with TACI-Ig

  2006cited by this paper
• BAFF, APRIL and human B cell disorders.

  2006cited by this paper
• Raised serum APRIL levels in patients with systemic lupus erythematosus

  2004cited by this paper
• Challenges in bringing the bench to bedside in drug development for sle

  2004cited by this paper
• Engineering an APRIL-specific B Cell Maturation Antigen*

  2004cited by this paper
• BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone.

  2004cited by this paper
• Epidemiology of systemic lupus erythematosus.

  2002cited by this paper
• Crystal structure of sTALL-1 reveals a virus-like assembly of TNF family ligands.

  2002cited by this paper
• Maturation of Marginal Zone and Follicular B Cells Requires B Cell Activating Factor of the Tumor Necrosis Factor Family and Is Independent of B Cell Maturation Antigen

  2001cited by this paper
• TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS.

  2001cited by this paper
• TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease

  2000cited by this paper
• Tumor Necrosis Factor (TNF) Receptor Superfamily Member TACI Is a High Affinity Receptor for TNF Family Members APRIL and BLyS*

  2000cited by this paper
• Mice Transgenic for Baff Develop Lymphocytic Disorders along with Autoimmune Manifestations

  1999cited by this paper
• BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth

  1999cited by this paper
• APRIL, a New Ligand of the Tumor Necrosis Factor Family, Stimulates Tumor Cell Growth

  1998cited by this paper

• Post-transplant IgA Nephropathy.

  2025cites this paper
• The TNFSF Members APRIL and BAFF and Their Receptors TACI, BCMA, and BAFFR in Oncology, With a Special Focus in Breast Cancer

  2020cites this paper
• Targeted Therapies in SLE

  2019cites this paper
• Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: Present and future perspectives.

  2019cites this paper
• The role of APRIL - A proliferation inducing ligand - In autoimmune diseases and expectations from its targeting.

  2018cites this paper
• Targeting B Cells and Plasma Cells in Glomerular Diseases: Translational Perspectives.

  2018cites this paper
• Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis

  2017cites this paper
• Fc-fusion Proteins in Therapy: An Updated View.

  2017cites this paper
• Recent Advances in the Treatment of Immune-Mediated Inflammatory Diseases.

  2016cites this paper
• Neutralizing BAFF/APRIL With Atacicept Prevents Early DSA Formation and AMR Development in T Cell Depletion Induced Nonhuman Primate AMR Model

  2015cites this paper
• Targeting B-cell maturation antigen in multiple myeloma.

  2015cites this paper
• The potential role of blisibimod for the treatment of systemic lupus erythematosus

  2014cites this paper
• Raised Expression of APRIL in Chinese Children With Acute Lymphoblastic Leukemia and its Clinical Implications

  2014cites this paper
• TACI-Fc gene therapy improves autoimmune sialadenitis but not salivary gland function in non-obese diabetic mice.

  2012cites this paper
• TACI-Fc gene therapy improves auto-immune sialadenitis but not salivary gland function in NOD mice

  2012cites this paper
• Local gene therapy and the identification of therapeutic targets in Sjögren’s syndrome

  2012cites this paper
• Local gene therapy and the identification of therapeutic targets in Sjögren’s syndrome

  2012cites this paper
• Neurobiology and Hormonal Control of Lacrimal and Salivary Gland Function

  2011cites this paper
• Development and characterization of APRIL antagonistic monoclonal antibodies for treatment of B-cell lymphomas.

  2011cites this paper
• A proliferation-inducing ligand (APRIL): the development of antagonistic agents as potential therapeutics and deciphering the role of heparan sulphate proteoglycans (HSPGs) in APRIL Signalling.

  2011cites this paper
• Interplay of Pathogenic TH1/TH17 Cells and Regulatory T Cells in Auto-immune Disease: A Tale of Yin and Yang

  2011cites this paper
• B‐cell stage and context‐dependent requirements for survival signals from BAFF and the B‐cell receptor

  2010influential citation
• B-lymphocyte homeostasis and BLyS-directed immunotherapy in transplantation.

  2010cites this paper
• The cytokine milieu in the interplay of pathogenic Th1/Th17 cells and regulatory T cells in autoimmune disease

  2010cites this paper
• Novel treatments for systemic lupus erythematosus.

  2010cites this paper
• Aktuelle therapeutische Optionen bei Sjögren-Syndrom

  2010cites this paper
• Update on emerging drug therapies for systemic lupus erythematosus

  2010cites this paper
• [Current therapeutic options in Sjögren's syndrome].

  2010cites this paper
• Immune system: part III. The delicate balance of the immune system between tolerance and autoimmunity

  2010cites this paper
• Control systems and decision making for antibody production

  2010cites this paper
• Contemporary treatment of systemic lupus erythematosus: an update for clinicians

  2010cites this paper
• Management of lupus nephritis-current perspectives

  2009cites this paper
• Fusion-proteins as biopharmaceuticals--applications and challenges.

  2009cites this paper
• B-cell tolerance in transplantation: is repertoire remodeling the answer?

  2009cites this paper